Nuvectis Pharma Management
Management criteria checks 1/4
Nuvectis Pharma's CEO is Ron Bentsur, appointed in Jul 2020, has a tenure of 4.5 years. total yearly compensation is $2.69M, comprised of 22.9% salary and 77.1% bonuses, including company stock and options. directly owns 17.29% of the company’s shares, worth $20.61M. The average tenure of the management team and the board of directors is 4.5 years and 2.8 years respectively.
Key information
Ron Bentsur
Chief executive officer
US$2.7m
Total compensation
| CEO salary percentage | 22.9% |
| CEO tenure | 4.5yrs |
| CEO ownership | 17.3% |
| Management average tenure | 4.5yrs |
| Board average tenure | 2.8yrs |
Recent management updates
Recent updates
Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans
Oct 20
We Think Nuvectis Pharma (NASDAQ:NVCT) Needs To Drive Business Growth Carefully
Jun 26Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?
Jan 06Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation
Oct 03We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate
Jan 31Nuvectis Pharma forms scientific advisory board for research and development of drugs
Sep 28Nuvectis Pharma GAAP EPS of -$0.28 misses by $0.04
Aug 05Nuvectis Pharma declines 13%, announces $15.9M private placement
Jul 27We're Keeping An Eye On Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate
May 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$19m |
| Jun 30 2024 | n/a | n/a | -US$21m |
| Mar 31 2024 | n/a | n/a | -US$22m |
| Dec 31 2023 | US$3m | US$615k | -US$22m |
| Sep 30 2023 | n/a | n/a | -US$22m |
| Jun 30 2023 | n/a | n/a | -US$22m |
| Mar 31 2023 | n/a | n/a | -US$20m |
| Dec 31 2022 | US$2m | US$420k | -US$19m |
| Sep 30 2022 | n/a | n/a | -US$15m |
| Jun 30 2022 | n/a | n/a | -US$13m |
| Mar 31 2022 | n/a | n/a | -US$16m |
| Dec 31 2021 | US$384k | n/a | -US$13m |
Compensation vs Market: Ron's total compensation ($USD2.69M) is above average for companies of similar size in the US market ($USD645.47K).
Compensation vs Earnings: Ron's compensation has increased whilst the company is unprofitable.
CEO
Ron Bentsur (58 yo)
4.5yrs
Tenure
US$2,690,725
Compensation
Mr. Ron Bentsur, M.B.A. is a Co-Founder of Nuvectis Pharma, Inc. on July 27, 2020 and serves as its Chairman, Chief Executive Officer and President. He has been Advisor of UroGen Pharma Ltd. since January...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 4.5yrs | US$2.69m | 17.29% $ 20.6m | |
| Co-Founder | 4.5yrs | US$1.56m | 8.07% $ 9.6m | |
| Co-Founder | 4.5yrs | US$1.56m | 8% $ 9.5m | |
| Vice President of Finance | 2.8yrs | no data | 0.72% $ 857.1k |
4.5yrs
Average Tenure
52.5yo
Average Age
Experienced Management: NVCT's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | no data | US$2.69m | 17.29% $ 20.6m | |
| Independent Director | 3.5yrs | US$60.00k | 0.30% $ 356.8k | |
| Member of Scientific Advisory Board | 2.3yrs | no data | no data | |
| Independent Director | 3.3yrs | US$50.00k | 0.43% $ 516.8k | |
| Member of Scientific Advisory Board | 2.3yrs | no data | no data | |
| Independent Director | 3.5yrs | US$60.00k | 0.53% $ 636.4k | |
| Member of Scientific Advisory Board | 2.3yrs | no data | no data |
2.8yrs
Average Tenure
57yo
Average Age
Experienced Board: NVCT's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 01:05 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nuvectis Pharma, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joseph Pantginis | H.C. Wainwright & Co. |
| Aydin Huseynov | Ladenburg Thalmann & Company |
| Jonathan Aschoff | Roth MKM |